Alnylam Pharmaceuticals. has filed a patent for a polynucleotide agent that targets the angiotensinogen (AGT) gene. The agent which is a single stranded antisense polynucleotide, can inhibit the expression of AGT and potentially treat AGT-associated diseases such as hypertension. The agent consists of 4 to 50 contiguous nucleotides, with at least one modified nucleotide, and has a nucleotide sequence that is about 80% complementary to specific regions of the AGT gene. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Antisense polynucleotide agent for inhibiting angiotensinogen expression
A recently filed patent (Publication Number: US20230310485A1) describes a single stranded antisense polynucleotide agent for inhibiting the expression of angiotensinogen (AGT). The agent consists of about 4 to about 50 contiguous nucleotides, with at least one modified nucleotide. The nucleotide sequence of the agent is about 80% complementary to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs: 1-4.
The patent also mentions that the agent can have at least 8 contiguous nucleotides that differ by no more than 3 nucleotides from any one of the nucleotide sequences listed in Table 3. The length of the agent can range from about 8 to about 50 nucleotides.
The nucleotides of the single stranded antisense polynucleotide agent can all be modified, and the length of the agent can vary from 10 to 40 nucleotides, 10 to 30 nucleotides, 18 to 30 nucleotides, 10 to 24 nucleotides, 18 to 24 nucleotides, or 20 nucleotides.
The nucleotide modifications of the agent can include a modified sugar moiety such as a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. Additionally, the nucleotide modifications can include a 5-methylcytosine or a modified internucleoside linkage.
The agent can also comprise a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide with a modified sugar moiety.
The patent further describes a pharmaceutical composition for inhibiting the expression of the angiotensinogen (AGT) gene, which includes the single stranded antisense polynucleotide agent.
Methods of inhibiting AGT expression in a cell and treating a subject with a disease or disorder that would benefit from a reduction in AGT expression are also disclosed in the patent. These methods involve contacting the cell with the single stranded antisense polynucleotide agent or administering the agent to the subject in a therapeutically effective amount.
Overall, this patent describes a novel single stranded antisense polynucleotide agent and its various modifications for inhibiting the expression of angiotensinogen (AGT). The agent has potential applications in pharmaceutical compositions and methods for treating diseases or disorders related to AGT expression.
To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
